Trials / Completed
CompletedNCT00647478
System-IGF-1 Pathway and Alzheimer's Disease
A Multicenter Study to Assess Differences Between Circulating Levels of IGF-I and IGFBP-3 in Patients With Sporadic Late-onset Alzheimer's Disease and Control Elderly Subjects.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 693 (actual)
- Sponsor
- Assistance Publique - Hôpitaux de Paris · Academic / Other
- Sex
- All
- Age
- 65 Years
- Healthy volunteers
- Accepted
Summary
The aim is to assess the relationship between levels of IGF-I system components and cognitive status in patients with Alzheimer's disease (AD), in elderly subjects with normal cognitive function, and in patients with mild cognitive impairment (MCI).
Detailed description
AD is the most common cause of dementia. During aging, decline of biological brain functions due to a number of genetic and environmental factors facilitates the onset of AD. MCI includes prodromal AD. The identification of the risk factors for AD must be a priority in order to define the best therapeutic approach. Recent data support the notion that IGF-I pathway accounts for neuronal protection, with a dual effect, on both brain Aβ peptide and tau protein. This large, multicenter, prospective, observational, cross-sectional population-based study in 3 parallel groups (200 participants per group) is aimed to assess differences between IGF-I and IGFBP3 circulating levels and polymorphisms in AD patients and control elderly subjects, and in MCI patients.
Conditions
- Alzheimer's Disease
- Mild Cognitive Impairment
- Cognitive Function 1, Social
- Control With Normal Activities of Daily Living
Timeline
- Start date
- 2007-10-01
- Primary completion
- 2010-10-01
- Completion
- 2012-07-01
- First posted
- 2008-03-31
- Last updated
- 2026-03-11
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT00647478. Inclusion in this directory is not an endorsement.